2型糖尿病对前列腺癌发病风险和预后的影响

刘芳; 王依洁; 单雄威; 魏强

doi:10.13201/j.issn.1001-1420.2016.10.024

2型糖尿病对前列腺癌发病风险和预后的影响

- 1. 南方医科大学第一临床医学院(广州,510515);
- 2. 南方医科大学南方医院泌尿外科
基金项目:
南方医科大学2015年校级大学生创新训练计划项目(编号201512121249)

详细信息

通讯作者: 魏强,E-mail:weiqiang0915@163.com

中图分类号: R737.25

收稿日期: 2016-07-27

Influence of type 2 diabetes mellitus on the risk and prognosis of prostate cancer

- 1. First Clinical Medical College,Southern Medical University,Guangzhou, 510515, China;
- 2. Department of Urology,Nanfang Hospital,Southern Medical University

More Information

Corresponding author: WEI Qiang, E-mail: weiqiang0915@163.com

Received Date: 27 July 2016

摘要

摘要: 2型糖尿病(T2DM)可增加多种恶性肿瘤的发病风险,如乳腺癌、结肠癌、胰腺癌等,但同时研究发现T2DM可降低前列腺癌(PCa)的发病风险,其影响PCa发病风险的主要因素包括:血糖水平、雄激素水平、前列腺癌特异抗原(PSA)水平、二甲双胍和胰岛素等。此外,近年来研究还发现这些因素同时也能增加PCa患者复发和死亡风险。本文就T2DM上述因素与PCa发病风险和预后关系做一综述。
- 前列腺癌 /
- 2型糖尿病 /
- 发病风险 /
- 预后
Abstract: A large number of epidemiological studies have shown that type 2diabetes mellitus (T2 DM) is a risk factor of malignant tumors,such as breast cancer,colorectal cancer,pancreatic cancer,etc.However,epidemiologic evidence provides strong support for the notion that T2 DM can decrease the risk of prostate cancer (PCa).Hypothesized mechanisms of decreasing PCa risk among T2 DM include blood glucose level,glycosylated hemoglobin (HbA1c) level,androgen level,prostate cancer specific antigen (PSA) level,metformin and insulin,etc.Moreover,T2 DM is associated with the recurrence and poor prognosis of PCa.This review describes the association between T2 DM and PCa from the points of the risk and prognosis of PCa.
- prostate cancer /
- type 2 diabetes mellitus /
- risk of disease /
- prognosis

HTML全文

参考文献(34)

[1]	Siegel R L,Miller K D,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
[2]	韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.
[3]	Fall K,Garmo H,Gudbjornsdottir S,et al.Diabetes mellitus and prostate cancer risk;a nationwide casecontrol study within PCBaSe Sweden[J].Cancer Epidemiol Biomarkers Prev,2013,22(6):1102-1109.
[4]	Onitilo A A,Stankowski R V,Berg R L,et al.Type 2diabetes mellitus,glycemic control,and cancer risk[J].Eur J Cancer Prev,2014,23(2):134-140.
[5]	Darbinian J A,Ferrara A M,Van Den Eeden S K,et al.Glycemic status and risk of prostate cancer[J].Cancer Epidemiol Biomarkers Prev,2008,17(3):628-635.
[6]	Barbosa-Desongles A,Hernandez C,De Torres I,et al.Diabetes protects from prostate cancer by downregulating androgen receptor:new insights from LNCaPcells and PAC120 mouse model[J].PLoS One,2013,8(9):174-179.
[7]	Drake I,Wallstrom P,Hindy G,et al.TCF7L2 type 2 diabetes risk variant,lifestyle factors,and incidence of prostate cancer[J].Prostate,2014,74(12):1161-1170.
[8]	Wright J L,Plymate S R,Porter M P,et al.Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer[J].Prostate Cancer Prostatic Dis,2013,16(2):204-208.
[9]	Biernacka K M,Uzoh C C,Zeng L,et al.Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2[J].Endocr Relat Cancer,2013,20(5):741-751.
[10]	Ozbek E,Otunctemur A,Dursun M,et al.Diabetes mellitus and HbA1c levels associated with high grade prostate cancer[J].Asian Pac J Cancer Prev,2014,15(6):2555-2558.
[11]	鲍文华,陈福军,杨泽.前列腺癌发病机制中雄激素和雄激素受体信号的作用[J].中国老年保健医学,2015,13(1):9-12.
[12]	Cai H,Xu Z,Xu T,et al.Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer:a meta-analysis of 11cohort studies[J].Diabetes Metab Res Rev,2015,31(4):336-343.
[13]	Xia J W,Tan S J,Zhang X L,et al.Correlation of serum testosterone with insulin resistance in elderly male type 2diabetes mellitus patients with osteoporosis[J].J Diabetes Investig,2015,6(5):548-552.
[14]	李丹丹,王迎宾,李骥,等.前列腺癌组织中TGF-β1、Ki-67的表达变化及意义[J].山东医药,2014,54(31):62-64.
[15]	Baradaran N,Ahmadi H,Salem S,et al.The protective effect of diabetes mellitus against prostate cancer:role of sex hormones[J].Prostate,2009,69(16):1744-1750.
[16]	Hsing A W,Chu L W,Stanczyk F Z.Androgen and prostate cancer:is the hypothesis dead[J]?Cancer Epidemiol Biomarkers Prev,2008,17(10):2525-2530.
[17]	Atan A,Tuncel A,Yesil S,et al.Serum testosterone level,testosterone replacement treatment,and prostate cancer[J].Adv Neurol,2013,2013:275945.
[18]	Turner E L,Lane J A,Donovan J L,et al.Association of diabetes mellitus with prostate cancer:nested case-control study(Prostate testing for cancer and treatment study)[J].Int J Cancer,2011,128(2):440-446.
[19]	Werny D M,Saraiya M,Gregg E W.Prostate-specific antigen values in diabetic and nondiabetic US men,2001-2002[J].Am J Epidemiol,2006,164(10):978-983.
[20]	刘刚,岳明,刘淳,等.血清PSA及PSA密度与前列腺癌分级分期的关系[J].临床泌尿外科杂志,2011,26(8):597-599.
[21]	Oh J J,Hong S K,Lee S,et al.Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy[J].Int Urol Nephrol,2013,45(1):121-127.
[22]	Patel T,Hruby G,Badani K.Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin[J].Urol J,2010,5(76):1240-1244.
[23]	Jayachandran J,Aronson W,Terris M,et al.Diabetes and outcomes after radical prostatectomy:are results affected by obesity and race?Results from the shared equal-access regional cancer hospital database[J].Cancer Epidemiol Biomarkers Prev,2010,1(19):9-17.
[24]	Preston M A,Riis A H,Ehrenstein V,et al.Metformin Use and Prostate Cancer Risk[J].Eur Urol,2014,66(6):1012-1020.
[25]	Lee S Y,Song C H,Xie Y B,et al.SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells[J].Cancer Lett,2014,354(2):390-397.
[26]	Stopsack K H,Ziehr D R,Rider J R,et al.Metformin and prostate cancer mortality:a meta-analysis[J].Cancer Causes Control,2016,27(1):105-113.
[27]	Margel D,Urbach D R,Lipscombe L L,et al.Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes[J].J Clin Oncol,2013,31(25):3069-3075.
[28]	Belda-Iniesta C,Pernia O,Simo R.Metformin:a new option in cancer treatment[J].Clin Transl Oncol,2011,13(6):363-367.
[29]	Akinyeke T,Matsumura S,Wang X,et al.Metformin targets c-MYC oncogene to prevent prostate cancer[J].Carcinogenesis,2013,34(12):2823-2832.
[30]	Hammarsten J,Damber J E,Peeker R,et al.A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer[J].Cancer Epidemiol,2010,34(5):574-579.
[31]	Lubik A A,Gunter J H,Hendy S C,et al.Insulin increases de novo steroidogenesis in prostate cancer cells[J].Cancer Res,2011,71(17):5754-5764.
[32]	Hitron A,Adams V,Talbert J,et al.The influence of antidiabetic medications on the development and progression of prostate cancer[J].Cancer Epidemiol,2012,36(4):243-250.
[33]	Tseng C H.Human insulin does not increase prostate cancer risk in Taiwanese[J].Clin Genitourin Canc,2014,12(1):7-12.
[34]	Lind M,Fahlen M,Eliasson B,et al.The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer:an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes[J].Prim Care Diabetes,2012,6(1):53-59.